Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1983 May;40(2):529–533. doi: 10.1128/iai.40.2.529-533.1983

Effect of indomethacin on the incidence of experimental Escherichia coli pyelonephritis.

M P Glauser, P B Francioli, J Bille, M Bonard, P Meylan
PMCID: PMC264887  PMID: 6341240

Abstract

In the presence of temporary obstruction (20 h), ascending Escherichia coli urinary infection leads to irreversible acute exudative pyelonephritis (AEP) in rats. The purpose of the present study was to investigate the early inflammatory events which take place in response to the presence of bacteria in the kidney parenchyma and lead to the development of AEP. Rats were given indomethacin before and during the obstructive phase of kidney infection and were sacrificed at different times thereafter. Although renal infection (as defined by bacterial counts) was equally frequent (76%) and severe in indomethacin-treated and control rats sacrificed at the end of the obstructive period, it was found that the incidence of AEP (as defined by the inflammatory response of the kidney elicited by bacteria) 2 days after removal of the obstruction was significantly reduced from 74% in controls given water to 48% in indomethacin-treated animals (P = 0.02). Rat kidneys without AEP had bacterial counts of 10(2)/g. Since indomethacin apparently had no direct antibacterial activity against E. coli and no effect on urine osmolalities, it is likely that the reduction in the incidence of AEP and the concomitant eradication of bacteria after removal of the obstruction was due to an effect of indomethacin that is related to the renal response to infection. This was possibly due to decreased inflammation, as indicated by the fact that when pyelonephritis developed in indomethacin-treated rats it was less severe than in controls. These results suggest that if inflammation can be mitigated when bacteria are present in the kidney during obstruction, the bacteria may be cleared spontaneously once the normal urinary flow is restored.

Full text

PDF
529

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BEESON P. B., GUZE L. B. Experimental pyelonephritis. I. Effect of ureteral ligation on the course of bacterial infection in the kidney of the rat. J Exp Med. 1956 Dec 1;104(6):803–815. doi: 10.1084/jem.104.6.803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. BRAUDE A. I., SHAPIRO A. P., SIEMIENSKI J. Hematogenous pyelonephritis in rats. I. Its pathogenesis when produced by a simple new method. J Clin Invest. 1955 Oct;34(10):1489–1497. doi: 10.1172/JCI103200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brooks S. J., Lyons J. M., Braude A. I. Immunization against retrograde pyelonephritis. I. Production of an experimental model of severe ascending Escherichia coli pyelonephritis without bacteremia in rats. Am J Pathol. 1974 Feb;74(2):345–358. [PMC free article] [PubMed] [Google Scholar]
  4. Fairley K. F., Carson N. E., Gutch R. C., Leighton P., Grounds A. D., Laird E. C., McCallum P. H., Sleeman R. L., O'Keefe C. M. Site of infection in acute urinary-tract infection in general practice. Lancet. 1971 Sep 18;2(7725):615–618. doi: 10.1016/s0140-6736(71)80066-1. [DOI] [PubMed] [Google Scholar]
  5. Fairley K. F., Whitworth J. A., Kincaid-Smith P., Durman O. Single-dose therapy in management of urinary tract infection. Med J Aust. 1978 Jul 15;2(2):75–76. doi: 10.5694/j.1326-5377.1978.tb131369.x. [DOI] [PubMed] [Google Scholar]
  6. Fang L. S., Tolkoff-Rubin N. E., Rubin R. H. Efficacy of single-dose and conventional amoxicillin therapy in urinary-tract infection localized by the antibody-coated bacteria technic. N Engl J Med. 1978 Feb 23;298(8):413–416. doi: 10.1056/NEJM197802232980802. [DOI] [PubMed] [Google Scholar]
  7. Ford-Hutchinson A. W., Walker J. R., Connor N. S., Oliver A. M., Smith M. J. Separate anti-inflammatory effects of indomethacin, flurbiprofen and benoxaprofen. J Pharm Pharmacol. 1977 Jun;29(6):372–373. doi: 10.1111/j.2042-7158.1977.tb11340.x. [DOI] [PubMed] [Google Scholar]
  8. Glauser M. P., Lyons J. M., Braude A. I. Prevention of chronic experimental pyelonephritis by suppression of acute suppuration. J Clin Invest. 1978 Feb;61(2):403–407. doi: 10.1172/JCI108951. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gleckman R., Crowley M., Natsios G. A. Therapy of recurrent invasive urinary-tract infections of men. N Engl J Med. 1979 Oct 18;301(16):878–880. doi: 10.1056/NEJM197910183011607. [DOI] [PubMed] [Google Scholar]
  10. Katler E., Weissmann G. Steroids, aspirin, and inflammation. Inflammation. 1977 Dec;2(4):295–307. doi: 10.1007/BF00921009. [DOI] [PubMed] [Google Scholar]
  11. Levison S. P., Levison M. E. Effect of indomethacin and sodium meclofenamate on the renal concentrating defect in experimental enterococcal pyelonephritis in rats. J Lab Clin Med. 1976 Dec;88(6):958–964. [PubMed] [Google Scholar]
  12. Murray T., Goldberg M. Chronic interstitial nephritis: etiologic factors. Ann Intern Med. 1975 Apr;82(4):453–459. doi: 10.7326/0003-4819-82-4-453. [DOI] [PubMed] [Google Scholar]
  13. STAMEY T. A., GOVAN D. E., PALMER J. M. THE LOCALIZATION AND TREATMENT OF URINARY TRACT INFECTIONS: THE ROLE OF BACTERICIDAL URINE LEVELS AS OPPOSED TO SERUM LEVELS. Medicine (Baltimore) 1965 Jan;44:1–36. doi: 10.1097/00005792-196501000-00001. [DOI] [PubMed] [Google Scholar]
  14. Schechter H., Leonard C. D., Scribner B. H. Chronic pyelonephritis as a cause of renal failure in dialysis candidates. Analysis of 173 patients. JAMA. 1971 Apr 19;216(3):514–517. [PubMed] [Google Scholar]
  15. Smolen J. E., Weissmann G. Effects of indomethacin, 5,8,11,14-eicosatetraynoic acid, and p-bromophenacyl bromide on lysosomal enzyme release and superoxide anion generation by human polymorphonuclear leukocytes. Biochem Pharmacol. 1980 Feb 15;29(4):533–538. doi: 10.1016/0006-2952(80)90373-1. [DOI] [PubMed] [Google Scholar]
  16. Thomas V., Shelokov A., Forland M. Antibody-coated bacteria in the urine and the site of urinary-tract infection. N Engl J Med. 1974 Mar 14;290(11):588–590. doi: 10.1056/NEJM197403142901102. [DOI] [PubMed] [Google Scholar]
  17. Weissmann G., Smolen J. E., Korchak H. M. Release of inflammatory mediators from stimulated neutrophils. N Engl J Med. 1980 Jul 3;303(1):27–34. doi: 10.1056/NEJM198007033030109. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES